PLACEBO
DeviceThe placebo device consists of the same hardware as GyroGlove: aesthetically it looks the same, weight same and produces the same noise as GyroGlove. Participants will interact with Placebo on the day of baseline visit (i.e. Day 0).
NCT Number: NCT05958030
This is a multi-centre, single-blind, placebo-controlled trial with an open label follow up. After the baseline assessment, all participants will receive the GyroGlove for two weeks during the open label follow up part of the trial. All gloves will be retrieved and returned to GyroGear after closure of the study.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Addenbrooke Hospital, Cambridge University Hospital NHS Trust, Cambridge, England, United Kingdom
All participants will attend 2 in-clinic assessment sessions (Baseline (day 0), Follow-up (day 14)) after screening visit. The baseline session will last approximately 120 minutes whilst the 2-week assessment will last approximately 60-80 minutes. At baseline assessment, participants will perform protocol-specific activities with both investigational devices (i.e. GyroGlove and Placebo).
In addition to in-clinic assessments, participants will complete self-assessments at Day -3 prior baseline visit (i.e. Day 0,) and at Day 5 and 10 from baseline (i.e. Day 0), when they started using GyroGlove at home.
All participants will be blinded at the baseline (Day 0), as assessments will be performed with GyroGlove and a placebo device in a pre-defined sequence. Each participant will act as the control for him/herself and will be blinded to the interventions order.
The sequence of interventions in the study has been pre-defined, owing to the potential for longitudinal effects of wearing the device interfering with the accurate study outcome measurement.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
And
Exclusion criteria
The placebo device consists of the same hardware as GyroGlove: aesthetically it looks the same, weight same and produces the same noise as GyroGlove. Participants will interact with Placebo on the day of baseline visit (i.e. Day 0).
GyroGlove is a patented wearable device containing high-performance, miniaturised, gyroscopes designed for individuals diagnosed with essential tremor. Participants will interact with GyroGlove on the day of baseline visit (i.e. Day 0), 2-week Home use and on the day of follow-up visit (i.e Day 14).
Time frame: Day-0 (Baseline) and Day-14 (follow-up)
The Essential Tremor Rating Assessment Scale (TETRAS) composite outcome score is the sum of modified items 2, 3, 6 & 8 of the TETRAS-ADL (Activities of Daily Living) subscale and modified items 6 - 7 of the TETRAS-PS (performance subscale). The TETRAS-ADL subscale is a patient-rated scale administered by a trained interviewer that assesses the impact of tremor on day-to-day functioning, such as feeding with a spoon, drinking from a glass, pouring, using keys etc. The TETARS-PS is a clinical rating scale that quantifies tremor in the head, face, voice, limbs and trunk. Items 6 (drawing an Archimedes spiral) and 7 (handwriting) of the TETRAS-PS evaluate the impact of upper limb tremor on performance. Each item from the modified subscales ranges from 0 - 4, with 0 representing normal and 4 representing severely abnormal. The sum of the 6 items provides the TETRAS composite outcome score, which ranges from 0 - 24, with higher scores representing more severe ET.
Time frame: Day-0 (Baseline)
TETARS-PS is a clinical rating scale that quantifies tremor in the head, face, voice, limbs and trunk. Items 6 (drawing an Archimedes spiral) and 7 (handwriting) of the TETRAS-PS evaluate the impact of upper limb tremor on performance. Each item from the modified subscales ranges from 0 - 4, with 0 representing normal and 4 representing severely abnormal. The sum of the TETRAS-PS items, which ranges from 0 - 8, with higher scores representing more severe ET.
Time frame: Day-0 (Baseline)
The CGI-I is a 7-point Likert-type rating scale that a qualified medical personnel (ie, a clinician)will use to rate the severity of the participants' ability to function due to their ET. The responses to this scale range from 1 (Very much improved) to 7 (Very much worse).
Time frame: Day-0 (Baseline)
The PGI-I is a 7-point Likert-type rating scale that participants use to rate the change in severity of their ability to function due to ET. The responses to this scale range from 1 (Very much better) to 7 (Very much worse).
Time frame: Upto Day-14
Safety outcome as measured by the incidence of investigational devices-related adverse events, event types from Day-0 (Baseline) to Day-14 (follow-up assessment)
Time frame: Day-0 (Baseline) and Day-14 (follow-up)
The Essential Tremor Rating Assessment Scale- Activities of Daily Living (TETRAS-ADL) subscale is a patient-rated scale administered by a trained interviewer that assesses the impact of tremor on day-to-day functioning, such as feeding with a spoon, drinking from a glass, pouring, using keys. Each item from the modified subscales ranges from 0 - 4, with 0 representing normal and 4 representing severely abnormal. The sum of the 4 items of TETRAS ADL subscale provide outcome score, which ranges from 0 - 16, with higher scores representing more severe ET.
Time frame: Day-0 (Baseline) and Day-14
The Quality of Life in Essential Tremor Questionnaire (QUEST) was developed to specifically assess the impact of ET on health-related quality of life. The QUEST is a 30-item questionnaire comprising 5 subscales (physical, psychosocial, communication, hobbies/leisure, and work/finance) and a total score, plus 3 additional items relating to sexual function and satisfaction with tremor control and medication side effects. Each item is rated by frequency on a scale from 0 (never) to 4 (always), with higher scores indicating greater dissatisfaction or disability due to ET.
Time frame: Day-0 (Baseline) and Day-14 (follow-up)
The PGI-I is a 7-point Likert-type rating scale that participants use to rate the change in severity of their ability to function due to ET. The responses to this scale range from 1 (Very much better) to 7 (Very much worse).
Time frame: Day-0 (Baseline) and Day-14 (follow-up)
TETARS-PS is a clinical rating scale that quantifies tremor in the head, face, voice, limbs and trunk. Items 6 (drawing an Archimedes spiral) and 7 (handwriting) of the TETRAS-PS evaluate the impact of upper limb tremor on performance. Each item from the modified subscales ranges from 0 - 4, with 0 representing normal and 4 representing severely abnormal. The sum of the TETRAS-PS items, which ranges from 0 - 8, with higher scores representing more severe ET.
Time frame: Day-0 (Baseline) and Day-14 (follow-up)
Health-related quality of life will be measured using the EuroQol Five Dimensions (EQ-5D). The EQ-5D-5L is a valid extension of the 3-level questionnaire. It can be defined as a standardized non-disease specific value-based instrument to describe and value health-related quality of life. The instrument consists of two components: the EQ-5D descriptive system and the EQ visual analogue scale (EQ-VAS).The first part consists of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response categories (no problems, slight problems, moderate problems, severe problems, and extreme problems). The EQ-VAS measures one's self-perceived health today on a vertical scale from 0 (worst imaginable health) to 100 (best imaginable health) on which participants have to indicate their current health.
Time frame: Day-1 to Day-14
Bain & Findley Activities of Daily Living (B&F ADL) Scale is a patient rated scale. ADL tasks included in the study are: Use a spoon to drink soup ; Hold a cup of tea ; Pour milk from a bottle or carton ; Dial a telephone ; Pick up your change ; Insert an electric plug into a socket ; Unlock your front door with a key and Write a letter. Each task will be rated on a 4-point scale (1-4): 1 = Able to do the activity without difficulty ; 2 = Able to do the activity with a little effort ; 3 = Able to do the activity with a lot of effort ; 4 = Cannot do the activity by yourself.
Time frame: Day-0 (Baseline) and Day-14 (follow-up)
The CGI-I is a 7-point Likert-type rating scale that a qualified medical personnel (ie, a clinician)will use to rate the severity of the participants' ability to function due to their ET. The responses to this scale range from 1 (Very much improved) to 7 (Very much worse).
Time frame: Day-14 (follow-up)
Change in participants' experience of GyroGlove after 2-week home use will be assessed by utilising User Experience Questionnaire. Participants will complete User Experience Questionnaire form during follow-up visit.
Contact information is provided by the study sponsor or research team.
GyroGear Ltd
Industry
Effectiveness and Safety of GyroGlove in Stabilising Hand Tremors in Essential Tremor
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07721272
Brain Diseases, Central Nervous System Diseases
Dallas, Texas, United States
View Trial DetailsNCT07531238
Central Nervous System Diseases, Essential Tremor
Geneva, Switzerland
View Trial DetailsNCT07508696
Central Nervous System Diseases, Essential Tremor
Leuven, Vlaams-Brabant, Belgium
View Trial DetailsNCT07433699
Central Nervous System Diseases, Essential Tremor
Philadelphia, Pennsylvania, United States
View Trial Details